|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 601 13th Street, NW |
Address2 | 11th Floor North |
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 3867-12
|
||||||||
|
6. House ID# 315600000
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Matthew Welsh |
Date | 7/20/2020 6:42:39 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Biosimilars, no specific bill
Prescription drug value issues, no specific bill
FDA issues, no specific bill
Issues related to International Pricing Index (IPI), no specific bill
S. 657 Drug Price Transparency Act
S. 658 Accelerated Drug Approval for Prescription Therapies Act
S. 660 Efficiency and Transparency in Petitions Act
S. 1895, Lower Health Care Costs Act, a comprehensive bill designed to improve healthcare transparency and reduce healthcare costs, including prescription drugs
H.R. 1499, Protecting Consumer Access Generic Drugs Act
H.R. 1344, Competitive Deals Resulting in Unleashed Generics and Savings (DRUGS) Act
S. 1169, Ensuring Timely Access to Generics Act
S. 1617, Second Look at Drug Patents Act
H.R. 1520, Purple Book Continuity Act
S. 977, Transparent Drug Pricing Act
S. 102, Prescription Drug Price Relief Act
S. 659, Biologic Patent Transparency Act
H.R. 1503, Orange Book Transparency Act
H.R. 2296, Fair Accountability and Innovative Research (FAIR) Drug Pricing Act
S. 1664, Prescription Drug Price Reporting Act
S.659 - the Biologics Patent Transparency Act
Supply Chain Issues, no specific bill
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Executive Office of the President (EOP), Commerce - Dept of (DOC), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
O'Brien |
|
|
|
Helen |
Rhee |
|
|
|
Rebecca |
Mandell |
|
|
|
Jesse |
Kerns |
|
|
|
L. Nicole |
Currie |
|
|
|
Greg |
Portner |
|
|
|
Victoria |
Blatter |
|
|
|
Howard |
Moon |
|
|
|
Ruth |
Hoffman |
|
|
|
Jordan |
Layson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 6800 - HEROES (Health and Economic Recovery Omnibus Emergency Solutions) Act and temporary access to Part B medicines at home
H.R. 266 - Paycheck Protection Program and Health Care Enhancement Act and temporary access to Part B medicines at home
H.R. 2693/S. 283 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2019
2021 Notice of Benefit and Payment Parameters (NBPP) rule and cost-sharing assistance.
H.R. 6179 - Increasing Access to Biosimilars Act of 2020
H.R. 4597/S. 3466 - the ACCESS for Biosimilars Act of 2020
H.R. 3 - Lower Prescription Drug Costs Now Act
H.R. 19/S. 3129 Lower Costs, More Cures ActS. 2543 Prescription Drug Pricing Reduction Act
Issues related to the 340B program, no specific bill
Medicare Part B coverage and reimbursement issues
Home administration for Part B medicines due to COVID-19
Issues related to International Pricing Index (IPI), no specific bill
Coding and reimbursement for biologics/biosimilars
Issues related to Part D redesign
Issues related to Part D rebate reform
Medicare Part D access issues for plan year 2020 and 2021, no specific bill
Issues related to Direct to Consumer Advertisement
patient affordability issues, including copay cards
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), Natl Economic Council (NEC), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
L. Nicole |
Currie |
|
|
|
Greg |
Portner |
|
|
|
Helen |
Rhee |
|
|
|
Rebecca |
Mandell |
|
|
|
Jesse |
Kerns |
|
|
|
Victoria |
Blatter |
|
|
|
William |
O'Brien |
|
|
|
Howard |
Moon |
|
|
|
Ruth |
Hoffman |
|
|
|
Jordan |
Layson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act
Issues related to Puerto Rico
H.R. 6443, Securing the National Supply Chain Act of 2020
H.R. 6930, Manufacturing API, Drugs, and Excipients (MADE) in America Act of 2020
Issues related to OECD negotiations on the taxation of global income
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
L. Nicole |
Currie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S. 124 Preserve Access to Affordable Generics Act
Issues related to drug patents and exclusivities (no bill)
H.R. 1520, Purple Book Continuity Act of 2019
H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019
S. 1224, The Stop STALLING Act
S. 1416, The Affordable Prescriptions for Patients Act, on product hopping and patent thicketing
S.659 - the Biologics Patent Transparency Act
H.R. 938 Bringing Low-cost Options and Competition while Keeping Incentives for New Generics
H.R. 5133 Affordable Prescriptions for Patients Through Promoting Competition
H.R. 3991 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
H.R. 2374 Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act
H.R. 2375 Preserve Access to Affordable Generics and Biosimilars Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Rhee |
|
|
|
Greg |
Portner |
|
|
|
L. Nicole |
Currie |
|
|
|
William |
O'Brien |
|
|
|
Rebecca |
Mandell |
|
|
|
Victoria |
Blatter |
|
|
|
Howard |
Moon |
|
|
|
Jesse |
Kerns |
|
|
|
Jordan |
Layson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |